Cost-Utility of Treatments for Pulmonary Arterial Hypertension: A Markov State-Transition Decision Analysis Model

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.29, Iss.10, 2009-10, pp. : 635-646

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Effectiveness of Ibandronate for the Prevention of Fractures in Inflammatory Bowel Disease-Related Osteoporosis: Cost-Utility Analysis Using a Markov Model

By Kreck Simon Klaus Jochen

PharmacoEconomics, Vol. 26, Iss. 4, 2008-01 ,pp. : 311-328

Adis International

Access to resources Recommend Favorite

Cost-Utility Analysis of Treatment with Olanzapine Compared with Other Antipsychotic Treatments in Patients with Schizophrenia in the Pan-European SOHO Study

By Knapp Martin Windmeijer Frank

PharmacoEconomics, Vol. 26, Iss. 4, 2008-01 ,pp. : 341-358

Adis International

Access to resources Recommend Favorite

A Cost-Utility Analysis of Losartan versus Atenolol in the Treatment of Hypertension with Left Ventricular Hypertrophy

By Anis Aslam H. Sun Huiying

PharmacoEconomics, Vol. 24, Iss. 4, 2006-01 ,pp. : 387-400

Adis International

Access to resources Recommend Favorite

Measuring Preferences for Cost-Utility Analysis: How Choice of Method May Influence Decision-Making

By McDonough Christine M. Tosteson Anna N.A.

PharmacoEconomics, Vol. 25, Iss. 2, 2007-01 ,pp. : 93-106

Adis International

Access to resources Recommend Favorite

Cost-benefit or cost-utility analysis?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 315, 2001-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite